Behavioral Programs for Diabetes Mellitus

Recommendations

Info

Author, Year & Country Comparison & Sample Size (Number randomized unless NR then # analyzed) Age, Male, Non-White, BMI/KG, HbA1c, Insulin Treatment Intervention Category & Description Total Duration Including all Phases (m); Intensity (# contacts, total contact time); Maintenance/Support Phase Duration Method of Communication (In-person, Mixed, Technology) Method of Delivery (Individual, Group, Mixed) & Presence of Supports Delivery Personnel (Non- HCP, Single HCP, Multidisciplinary) Degree of Tailoring Community Engagement Samuel- Hodge, 2009 U.S. (NC) Sarkadi, 2004 Sweden I= 117 UC= 84 I= 39 UC= 38 7.4±1.2%, 14.4% I 2= 66.1±8y 46%, NR 29.6±4.6kg/m 2 7.1±1.3%, 14.2% I= 57.0y 36%, 100% 34.6kg/m 2 7.7%, 51% UC= 61.3y 37%, 100% 35.1kg/m 2 7.9%, 38% I= 66.4±7.9y NR, NR 27.2±3.6kg/m 2 6.5+_0.5%, NR UC= 66.5±10.7y NR, NR 28.6±5.8kg/m 2 6.5±0.5%, NR Education as per Spanish recommendation I 2 = DSME; PRECEDE model focusing on predisposing, enabling and reinforcing factors for behaviors identified via assessment DSME + Support; church-based diabetes selfmanagement program for African Americans DSME; pharmacist-led, experience and empowermentbased group education I 2= 24m; 10, 6.7h; NA 12m; 25, 19h+telephone call time;4m Mixed Mixed Non-HCP (church health advisor) & Multidisciplinary (RD, other HCP) 12m; 12, NR; NA In-person Group HCP (Pharmacist) I 2= Moderateto-High – Content & Delivery Moderate-to- High – Content & Delivery Moderate-to- High - Content Sevick, 2012 I= 147 I= 25 - >75y I=DSME; SCT- I= 6m; 14, NR; I= In-person I= Group I= I= Moderate- I= I 2= None/NR Yes None/NR F-46
Author, Year & Country Comparison & Sample Size (Number randomized unless NR then # analyzed) Age, Male, Non-White, BMI/KG, HbA1c, Insulin Treatment Intervention Category & Description Total Duration Including all Phases (m); Intensity (# contacts, total contact time); Maintenance/Support Phase Duration Method of Communication (In-person, Mixed, Technology) Method of Delivery (Individual, Group, Mixed) & Presence of Supports Delivery Personnel (Non- HCP, Single HCP, Multidisciplinary) Degree of Tailoring Community Engagement U.S. (PA) Att. C= 149 Shibayama, 2007 Japan I= 67 UC= 67 29.0%, 31.3% 34.0±7.3kg/m 2 7.7±2.2%, NR Att. C= 25 - >75y 34.8%%, 28.8% 35.1±7.7kg/m 2 7.5±1.7%, NR I= 61±8y 65.2%, NR 26±5kg/m 2 7.4±0.7%, 0% based intervention with technologybased selfmonitoring of SNBG, diet and PA Att. C= basic group education and mailed magazines; also received meter and pedometer DSME; nurse-led DSME NA Att. C= 6m; 3, NR:NA 12m; 12, 5.5h; NA Att. C= Inperson Att. C= Group Multidisciplinary (RD, RN) Att. C= HCP (RN) to-High – Content Att. C= None In-person Individual HCP (RN) Moderate-to- High – Content & Delivery None/NR Att. C= None/NR None/NR Sigurdardottir, 2009 Iceland I= 30 UC= 28 UC= 62±7y 65.2%, NR 26±5kg/m 2 7.4±0.7%, 0% I= 57.8±10.9y 64%, NR 31.5±5.1kg/m 2 8.1±0.9%, 39% UC= 63.5±9.3y 72%, NR 32.7±5.0kg/m 2 7.9±8.9%, 20% DSME; nurse-led empowerment approach using self-completed instruments on self-care and quality of life 1.5m; 6, 2.3- 3.7h; NA Mixed Individual HCP (RN) Moderate-to- High – Content & Delivery Siminerio, I 1= 32 I 1= 60±12y I 1= DSME; I 1= 6m; NR, NR; I 1= In-person I 1= Individual I 1= HCP (CDE) I 1= Moderate- I 1= None/NR F-47
Page 1 and 2:
Evidence Report/Technology Assessme
Page 3 and 4:
This report is based on research co
Page 5 and 6:
Key Informants In designing the stu
Page 7 and 8:
Peer Reviewers Prior to publication
Page 9 and 10:
HbA 1c reduction were more often de
Page 11 and 12:
KQ 6. Subgroups for Factors Moderat
Page 13 and 14:
Figure 13. Behavioral programs for
Page 15 and 16:
glycemia in reducing the incidence
Page 17 and 18:
together with one or more additiona
Page 19 and 20:
Figure A. Analytic framework for be
Page 21 and 22:
Methods Literature Search Strategy
Page 23 and 24:
With input from our Technical Exper
Page 25 and 26:
participants had suboptimal baselin
Page 27 and 28:
duration of diabetes ranged from 2.
Page 29 and 30:
Table B. Type 1 diabetes: summary o
Page 31 and 32:
T2DM: Description and Risk of Bias
Page 33 and 34:
Figure D. Plot of network meta-anal
Page 35 and 36:
The positive findings for behaviora
Page 37 and 38:
elated to the Human Development Ind
Page 39 and 40:
Table D. Potential research needs b
Page 41 and 42:
References 1. Renders CM, Valk GD,
Page 43 and 44:
37. Chodosh J, Morton SC, Mojica W,
Page 45 and 46:
Introduction Background The high bu
Page 47 and 48:
Factors other than blood glucose co
Page 49 and 50:
may include interventions related t
Page 51 and 52:
programs. The overarching boxes (co
Page 53 and 54:
Figure 2. Analytic framework for be
Page 55 and 56:
American Diabetes Association, Amer
Page 57 and 58:
Table 1. Inclusion criteria for typ
Page 59 and 60:
S1 in the Supplementary File). The
Page 61 and 62:
clinically significant); we refer t
Page 63 and 64:
Synthesis for T1DM (KQs 1-4) KQ 1:
Page 65 and 66:
conducted for HbA 1c and body mass
Page 67 and 68:
Applicability We followed the Metho
Page 69 and 70:
Type 1 Diabetes Mellitus This secti
Page 71 and 72:
therapy, 90,99,108 motivational enh
Page 73 and 74:
and a peer (with diabetes and train
Page 75 and 76:
followup (low SOE for both); there
Page 77 and 78:
Figure 6. Behavioral programs for t
Page 79 and 80:
similar results were found for yout
Page 81 and 82:
HbA 1c : Comparative Effectiveness
Page 83 and 84:
Two trials reported on adherence to
Page 85 and 86:
Table 4. Other clinical and behavio
Page 87 and 88:
Figure 14. Behavioral programs for
Page 89 and 90:
Health-Related Quality of Life: Beh
Page 91 and 92:
estimated effects were imprecise an
Page 93 and 94:
Table 8. Type 1 diabetes: summary o
Page 95 and 96:
Summary of Key Findings and Strengt
Page 97 and 98:
studies 82,94,95,105,109,112 were n
Page 99 and 100:
studied a DSME program in patients
Page 101 and 102:
I 2 =74%), 135,137,139,141,142,145,
Page 103 and 104:
Aerobic Fitness Test which estimate
Page 105 and 106:
Key Points: Body Mass Index • Lif
Page 107 and 108:
Table 12. Network meta-analysis for
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Figure 20. Plot of network meta-ana
Page 115 and 116:
active comparator (20 trials, 7,709
Page 117 and 118:
Discussion Key Findings and Discuss
Page 119 and 120:
to be tempered by the findings of n
Page 121 and 122:
compared with usual care. There was
Page 123 and 124:
Our finding that single-topic, non-
Page 125 and 126:
In their systematic review and meta
Page 127 and 128:
For studies targeting adults, the m
Page 129 and 130:
environmental contextual factors—
Page 131 and 132:
assessors was also rarely reported,
Page 133 and 134:
Tailoring programs to ethnic minori
Page 135 and 136:
17. Centers for Disease Control and
Page 137 and 138:
53. Medical Advisory Secretariat. B
Page 139 and 140:
88. Ellis DA, Templin T, Naar-King
Page 141 and 142:
122. Nansel TR, Iannotti RJ, Simons
Page 143 and 144:
158. Cooper H, Booth K, Gill G. A t
Page 145 and 146:
191. Koo BK, Han KA, Ahn HJ, et al.
Page 147 and 148:
224. Sevick MA, Korytkowski M, Ston
Page 149 and 150:
260. Yuan C, Lai CW, Chan LW, et al
Page 151 and 152:
295. Ayling K, Brierley S, Johnson
Page 153 and 154:
Appendix A. Operational Definitions
Page 155 and 156:
the structured diet or physical act
Page 157 and 158:
Appendix B. Literature Search Strat
Page 159 and 160:
1. MeSH descriptor: [Diabetes Melli
Page 161 and 162:
35. “blood glucose” N2 monitor*
Page 163 and 164:
35. (behavio?r adj2 therap*).mp. 36
Page 165 and 166:
52. exp animals/ not humans.sh. 53.
Page 167 and 168:
57. "Follow-Up Studies"[Mesh] 58. "
Page 169 and 170:
URL provided by Michelle Crain, AAD
Page 171 and 172:
WHO ICTRP Trial Registry: WHO ICTRP
Page 173 and 174:
Appendix D. Studies Excluded After
Page 175 and 176:
Health. 2006;6:134. PMID: 16709243.
Page 177 and 178:
November/December;24(9):450-6. PMID
Page 179 and 180:
89. Dinneen SF, O'hara MC, Byrne M,
Page 181 and 182:
119. Fitzpatrick SL, Jeffery R, Joh
Page 183 and 184:
Aug;19(8):835-42. PMID: 8842601. Ex
Page 185 and 186:
adherence and metabolic control. Di
Page 187 and 188:
May;36(5):1297-303. PMID: 23223405.
Page 189 and 190:
244. Korytkowski MT, Koerbel GL, Ko
Page 191 and 192:
275. Maljanian R, Grey N, Staff I,
Page 193 and 194:
306. Naccashian Z. The impact of di
Page 195 and 196:
led structured program on blood glu
Page 197 and 198:
Engineering. 2014;75(1-B E). PMID:
Page 199 and 200:
395. Skoro-Kondza L, Tai SS, Gadelr
Page 201 and 202:
426. Torbjornsen A, Jenum AK, Smast
Page 203 and 204:
Americans with type 2 diabetes. J A
Page 205 and 206:
patients. Diabetes Res Clin Pract.
Page 207 and 208:
Table E1. Risk of bias for studies
Page 209 and 210: Weinger, 2011 L M NA M NA L NA L L
Page 211 and 212: Cramer, 2007 M M H M H L H H L M H
Page 213 and 214: Ridgeway, 1999 M M H M H L H H M L
Page 215 and 216: Appendix F. Description of Studies
Page 217 and 218: Author, Year & Country Comparison &
Page 225 and 226: Table F3. Description of studies an
Page 259: Author, Year & Country Comparison &
Page 277 and 278: Appendix H. Strength of Evidence Ta
Page 279 and 280: Outcome # Trials (# Subjects); Tool
Page 281 and 282: Table H3. Behavioral programs compa
Page 283 and 284: 16. Mayer-Davis EJ, Seid M, Crandel
Page 285 and 286: Table I1. Effectiveness of behavior
Page 287 and 288: Category Health Outcomes Outcomes A
Page 289 and 290: Table I2. Effectiveness of behavior
Page 291 and 292: Category Outcomes Timepoint Health
Page 293 and 294: Outcome Change in Body Composition
Page 295 and 296: Outcome Change in Physical Activity
Page 297 and 298: References for Appendix I 1. Adachi
Page 299 and 300: 32. Rock CL, Flatt SW, Pakiz B, et
Page 301 and 302: follow-up study. Diabetes Res Clin
Page 303 and 304: 98. Johnson ST, Bell GJ, Mccargar L
Page 305 and 306: Appendix J. Network Meta-Analysis R
Page 307 and 308: 5 11-26h In person Group only NA -0
Page 309 and 310: 9 11-26h In person Group only NA -0
show all

Behavioral Programs for Diabetes Mellitus

Create successful ePaper yourself

Delete template?

Save as template?